EA200970704A1 - ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ - Google Patents

ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ

Info

Publication number
EA200970704A1
EA200970704A1 EA200970704A EA200970704A EA200970704A1 EA 200970704 A1 EA200970704 A1 EA 200970704A1 EA 200970704 A EA200970704 A EA 200970704A EA 200970704 A EA200970704 A EA 200970704A EA 200970704 A1 EA200970704 A1 EA 200970704A1
Authority
EA
Eurasian Patent Office
Prior art keywords
3alkyl
ring
6alkyl
nitrogen
pharmaceutical compositions
Prior art date
Application number
EA200970704A
Other languages
English (en)
Inventor
Джузеппе Альваро
Чарльз Лардж
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970704A1 publication Critical patent/EA200970704A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям, содержащим антагонист NK1 рецептора и блокатор натриевых каналов формулы (I)в которой Rи Rнезависимо представляют водород, Cалкил или СциклоалкилСалкил; или Rи Rвместе с атомом азота, к которому они присоединены, могут образовывать незамещенное 3-, 4-, 5- или 6-членное насыщенное кольцо; Rпредставляет Cалкил, Cгалогеналкил, CалкоксиСалкил или СгалогеналкоксиСалкил; или Rи Rвместе с соединяющими их атомами образуют насыщенное или ненасыщенное 4-6-членное кольцо; Х представляет атом углерода или атом азота; n равно 0, 1 или 2, где каждый Rпри его наличии независимо выбирают из группы, состоящей из Cалкила, галогена, циано, галогенСалкила, гидрокси, Cалкокси и Cгалогеналкокси; q равно 1 или 2; один из Rи Rпредставляет -O-Rили -OCHR, а другой Rили Rпредставляет водород или R; и где Rпредставляет фенильное кольцо или 5- или 6-членное ароматическое гетероциклическое кольцо (независимо содержащее один или более атомов азота, серы или кислорода), где фенильное кольцо или гетероциклическое кольцо необязательно замещено одной или более группами, независимо выбранными из группы, состоящей из Cалкила, галогена, циано, галогенСалкила, гидрокси, Cалкокси и Cгалогеналкокси; или его фармацевтически приемлемую соль или сольват, в виде комбинированного препарата для одновременного или последовательного введения, и к применению данных композиций для лечения определенных расстройств, включая эпилепсию и расстройства настроения.
EA200970704A 2007-01-24 2008-01-21 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ EA200970704A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0701366.7A GB0701366D0 (en) 2007-01-24 2007-01-24 Novel pharmaceutical compositions
PCT/EP2008/050622 WO2008090115A1 (en) 2007-01-24 2008-01-21 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers

Publications (1)

Publication Number Publication Date
EA200970704A1 true EA200970704A1 (ru) 2010-02-26

Family

ID=37872717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970704A EA200970704A1 (ru) 2007-01-24 2008-01-21 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ

Country Status (14)

Country Link
US (1) US20090326032A1 (ru)
EP (1) EP2117562B1 (ru)
JP (1) JP2010516732A (ru)
KR (1) KR20090102867A (ru)
CN (1) CN101641102A (ru)
AT (1) ATE530187T1 (ru)
AU (1) AU2008208918A1 (ru)
BR (1) BRPI0807968A2 (ru)
CA (1) CA2676172A1 (ru)
EA (1) EA200970704A1 (ru)
GB (1) GB0701366D0 (ru)
MX (1) MX2009007915A (ru)
TW (1) TW200940509A (ru)
WO (1) WO2008090115A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
SG11201607332UA (en) 2014-03-07 2016-10-28 Hoffmann La Roche Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US10421716B2 (en) 2014-12-23 2019-09-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
PL3270915T3 (pl) 2015-03-16 2020-08-24 F. Hoffmann-La Roche Ag Leczenie skojarzone z zastosowaniem agonisty tlr7 i inhibitora składania kapsydu hbv
EP3512556B1 (en) 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US11192856B2 (en) 2017-10-05 2021-12-07 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
SG11202002707VA (en) 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
AU2020249331A1 (en) 2019-03-25 2021-09-23 F. Hoffmann-La Roche Ag Solid forms of a compound of HBV core protein allosteric modifier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators

Also Published As

Publication number Publication date
CA2676172A1 (en) 2008-07-31
US20090326032A1 (en) 2009-12-31
EP2117562B1 (en) 2011-10-26
WO2008090115A1 (en) 2008-07-31
CN101641102A (zh) 2010-02-03
TW200940509A (en) 2009-10-01
JP2010516732A (ja) 2010-05-20
ATE530187T1 (de) 2011-11-15
KR20090102867A (ko) 2009-09-30
MX2009007915A (es) 2009-07-31
EP2117562A1 (en) 2009-11-18
GB0701366D0 (en) 2007-03-07
BRPI0807968A2 (pt) 2014-06-10
AU2008208918A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
EA200970705A1 (ru) Новые фармацевтические композиции
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
DE60320012D1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
DK1786790T3 (da) Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
EA200700099A1 (ru) Производные пиридина
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
AR036596A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
MX2012008533A (es) Naftiridinas sustituidas y su uso como inhibidores de syk quinasa.
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
JO2696B1 (en) Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
MX2012008147A (es) Derivados de pirrazolopiridina.
EA200970426A1 (ru) Селективный агонист tr-бета 1
MX362478B (es) Derivado de benzoazepina novedoso y uso medico del mismo.
ATE455095T1 (de) Vanilloidrezeptor trpv1-antagonisten
EA201071259A1 (ru) Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина